All News
@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains.
Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for
#EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
Links:
David Liew drdavidliew ( View Tweet)
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT.
ASAS20: 51% vs 9%; ASAS40: 23% vs 3%.
Promising app-based intervention comprising individualised exercise, pt education & disease Mx.
@RheumNow #EULAR2025 #LB0002
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2025 @eular_org update
#Recommendations #Rheumatoid #Rx
prof Smolen
subtle diff between former guidelines
MTX+GC
👇
D/C GCs rapidly
👇
If inadequate response
👇
Other csDMARDs are OUT ❎
✅go to bDMARD or tsDMARD*
TsDMARD after safety assessed
@RheumNow RecommendatnII https://t.co/yUrLdk6Eg1
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#LB0002 Crossover RCT of use of AXIA - a novel app-based intervention showed improvement in disease activity, functionality & quality of life in pople with Axial #SpA vs usual care. Available in Austria currently - awaiting rollout and in other languages @RheumNow https://t.co/nV4QifyikL
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#RA #recommendations #update
Some recommendations were merged
For sure some regions will consider
#Combination #csDMARDs or
Switch to another
👇🤔
#sulfasalazine
#leflunomide
Depends on access, pt preference, disease activity/severity
#EULAR2025 @RheumNow @eular_org https://t.co/QDPcHhvQiV
Janet Pope Janetbirdope ( View Tweet)
Presenting our abstract on remote monitoring in rheumatology at #EULAR2025 @RBNHSFT @UniofReading @HenleyBSchool @RheumNow https://t.co/palWjtX3gM
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Leaky pipeline in rheumatology:
In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men.
Top reasons?
🚫 Unfair promotion
🚫 Poor communication
🚫 No career path
Workplace equity still lags.
POS0407 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens.
⭐️🌱STAR/CRESS response rates also favoured active treatment.
Safe, accessible, affordable option for active disease.
@RheumNow #EULAR2025 #LB0005
Mrinalini Dey DrMiniDey ( View Tweet)
Recommendations for RA management at #EULAR2025
- MTX [or other csDMARDs] and steroids still remain the first line- nothing beats that!
- ofcourse minimize steroids!
- rather than stopping meds at remission, reducing doses may be a better solution.
Not much changed.
@RheumNow https://t.co/NK5ejsgjWV
Bella Mehta bella_mehta ( View Tweet)
Proud to present the 1st #ARCH_ArLAR prospective interventional study #EULAR2025
Large awareness campaign ➡️
🔺️Proportion new referred CIRDs pts ⬆️ from 31 to 37%
🔺️Time 2 see a rheuma ⬇️ 14 to 10 mo
🔺️Time 2 diagnosis ⬇️ 18 to 12 mo
POS1310
@RheumNow
@ArLARheumatolog https://t.co/eKrRKHNXMZ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The transformative potential of integrating ePROMs into AI care pathways
🔺️Study by Dr Antoni Chan et al. achieved a new-to-followup ratio of 1:2.5 outperforming the national average of 1:4.2
🔺️Without losing contact with pts
@synovialjoints
POS1271
#EULAR2025
@RheumNow https://t.co/z3jO3ADHR1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Why do Rheumatologists shift to private practice? Are there gender based differences?
A survey of 100+ European rheumatologists
Female 🚺 rheumatologists:
Leave hospital earlier
At a lower hierarchical level
Reasons for leaving:
nightshifts
unfair promotion decisions
Aurelie Najm AurelieRheumo ( View Tweet)
EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent dis
+
4️⃣ Exclude drivers like comorbidities & psychosocial factors
🔺️Exclude failure due to Side Effets/CI
#EULAR2025
@RheumNow https://t.co/ULD2Xe6p6A
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Imagine #Barcelona with an additional 8 degrees in summer 🔥 🔥🔥
Session: Disaster Medicine - Impact of climate change, heat, and global insecurity
#EULAR2025
@RheumNow https://t.co/1TqlBJtoZD
Nelly ZIADE 🍀 Nellziade ( View Tweet)
RA is worst with temperature rising/ climate change.
However SpA has the opposite effect!
Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD
Bella Mehta bella_mehta ( View Tweet)
Genicular artery embolisation is like so many interventions in MSK medicine:
early promise with smaller RCT & observational data, but the later, more robust data doesn’t show the same benefit.
If you do meta-analyses of all these data, you mix good with bad
#EULAR2025 @RheumNow https://t.co/K1tN9KX8rq
David Liew drdavidliew ( View Tweet)
Social disparities in rheumatology @RheumNow #EULAR2025
~70% of outcomes are determined by Social determinants of health
Modifiable factors ? Maybe? https://t.co/UfC2nQ5Azy
Bella Mehta bella_mehta ( View Tweet)
@RheumNow Achieving health equity is the goal
1.4% of GDP is lost in health inequity in EU https://t.co/50M4SfuxvX
Bella Mehta bella_mehta ( View Tweet)
